|Free Dividend Report|
|Stock Splits Calendar|
|MDVN Stock Split History|
|Preferred Stock Newsletter|
|MDVN Options Chain|
|Stock Message Boards|
MDVN (MDVN) has 2 splits in our MDVN split history database. The first split for MDVN took place on September 24, 2012. This was a 2 for 1 split, meaning for each share of MDVN owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split. MDVN's second split took place on September 16, 2015. This was a 2 for 1 split, meaning for each share of MDVN owned pre-split, the shareholder now owned 2 shares. For example, a 2000 share position pre-split, became a 4000 share position following the split.
When a company such as MDVN splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the MDVN split history from start to finish, an original position size of 1000 shares would have turned into 4000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into MDVN shares, starting with a $10,000 purchase of MDVN, presented on a split-history-adjusted basis factoring in the complete MDVN split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||48.45%|
|Medivation is a biopharmaceutical company focused on the development and commercialization of therapies to treat diseases. Co. has one commercial product, XTANDI® (enzalutamide) capsules (XTANDI), through its collaboration with Astellas Pharma, Inc. XTANDI has marketing approval in the U.S., Europe and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer, and in Japan for the treatment of patients with castration-resistant prostate cancer. Co. also has worldwide rights to talazoparib (MDV3800), an orally available poly-ADP ribose polymerase inhibitor, and pidilizumab (MDV9300), an antibody with immune-mediated anti-tumor effects. According to our MDVN split history records, MDVN has had 2 splits.|
|MDVN Split History Table|
|09/24/2012||2 for 1|
|09/16/2015||2 for 1|
|Healthcare Stock Splits|
|MDVN is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:|